Pfizer weighs sale of Philly-area campus—where 2,000 once worked—as company mulls when and how to bring employees back

Not only do corporations have to determine when to bring employees back into the office after more than a year of at-home work, but how. It’s a decision even major COVID-19 drugmakers are evaluating as they continue to develop and manufacture medicines and vaccines to combat the virus.

Take Pfizer, which said it’s considering the sale of its 1.89-million-square-foot office and laboratory space in Collegeville, Pennsylvania, as the company searches for a more “modern and flexible” workspace for returning employees, The Philadelphia Business Journal first reported Tuesday.